Fms related receptor tyrosine kinase 3. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Sunitinib CHEMBL535 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
✓ Both | 21 |
| Gilteritinib CHEMBL3301622 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
✓ Both | 19 |
| Sorafenib CHEMBL1336 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
✓ Both | 15 |
| Famitinib CHEMBL1278146 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
ChEMBL only | 11 |
| Pacritinib CHEMBL2035187 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Quizartinib CHEMBL576982 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Midostaurin CHEMBL608533 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
✓ Both | 5 |
| Fedratinib CHEMBL1287853 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Sunitinib Malate CHEMBL1567 |
Tyrosine-protein kinase receptor FLT3 inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Non-small cell lung carcinoma | 5 | Phase 3 |
| Acute myeloid leukemia | 4 | Phase 3 |
| Breast cancer | 4 | Phase 3 |
| Colorectal cancer | 4 | Phase 3 |
| Myelodysplastic syndrome | 4 | Phase 3 |
| Acute lymphoblastic leukemia | 4 | Phase 2 |
| Chronic myelomonocytic leukemia | 3 | Phase 2 |
| Leukemia | 3 | Phase 2 |
| Cervical cancer | 2 | Phase 3 |
| Differentiated thyroid carcinoma | 2 | Phase 3 |
| Exocrine pancreatic carcinoma | 2 | Phase 3 |
| Hepatocellular carcinoma | 2 | Phase 3 |
| Kidney cancer | 2 | Phase 3 |
| Renal cell adenocarcinoma | 2 | Phase 3 |
| B-cell chronic lymphocytic leukemia | 2 | Phase 2 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
